文献速递角膜与眼表疾病

甘草酸用于多重耐药铜绿假单胞菌:体外与体内研究

Glycyrrhizin Use for Multi-Drug Resistant Pseudomonas aeruginosa: In Vitro and In Vivo Studies.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2019-01-01

本研究在体外和角膜炎小鼠模型中测试甘草酸(GLY)对多重耐药铜绿假单胞菌的作用及其与环丙沙星的相互作用。GLY改变细菌膜通透性、降低活力并减少外排泵mRNA表达;在C57BL/6小鼠中,GLY联合环丙沙星较单用环丙沙星显著降低临床评分、平板计数和MPO。

要点

  • MDR9对6/12种抗生素耐药,B1045对7/12种耐药,两者均对环丙沙星耐药。
  • GLY对MDR9的MIC为40 mg/mL,对B1045为15 mg/mL。
  • 环丙沙星与GLY联用时MIC由32 μg/mL降至16 μg/mL。

核心结论

  • GLY通过改变细菌活力及外排泵活性等参数降低多重耐药性,并在体内增强环丙沙星疗效,减少眼部疾病、平板计数和MPO活性。

研究设计与样本

  • 体外研究结合C57BL/6小鼠角膜炎模型,比较MDR9(非眼部来源)与B1045(眼部来源)分离株,并检测GLY与环丙沙星联合效果。

主要发现

  • MDR9对6/12种抗生素耐药,B1045对7/12种耐药,两者均对环丙沙星耐药。
  • GLY对MDR9的MIC为40 mg/mL,对B1045的MIC为15 mg/mL。
  • 环丙沙星MIC为32 μg/mL,与GLY联用后降至16 μg/mL。
  • GLY改变细菌膜通透性并降低活力;蛋白质组学显示MDR9较PAO1外排泵增加,GLY降低其mRNA表达水平,溴化乙锭试验提示外排泵活性降低。
  • 在C57BL/6小鼠中,感染后18小时开始治疗,GLY联合环丙沙星组较单用环丙沙星组显著降低临床评分、平板计数和MPO。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Our purpose was to test glycyrrhizin (GLY) effects and ciprofloxacin interactions on multidrug resistant (MDR) isolates of Pseudomonas aeruginosa in vitro and in vivo in a mouse model of keratitis. METHODS: A Hardy-disk tested antibiotic sensitivity of isolates MDR9 (nonocular) and B1045 (ocular). GLY MIC (both isolates) and ciprofloxacin was determined spectrophotometrically. A live/dead assay using confocal microscopy and plate count, tested GLY effects on bacterial permeabilization/viability. Proteomics profiled bacterial efflux pumps (MDR9 vs. PAO1); RT-PCR comparatively tested GLY effects on their mRNA expression levels. The activity of efflux pumps was tested using ethidium bromide (EB); and scanning electron microscopy (SEM) visualized the effects of GLY treatment of bacteria. A combination of GLY and ciprofloxacin was tested in C57BL/6 mice (begun 18 hours after infection) and disease scored, photographed and MPO and plate counts done. RESULTS: MDR9 was resistant to 6/12 and B1045 to 7/12 antibiotics (both to ciprofloxacin). MIC GLY for MDR9 was 40 mg/mL and 15 mg/mL for B1045. Ciprofloxacin MIC (32 μg/mL) was reduced 2-fold to 16 μg/mL when ciprofloxacin and GLY were combined. GLY altered bacterial membrane permeability and reduced viability. Proteomics revealed increased efflux pumps in MDR9 versus PAO1; GLY reduced their mRNA expression levels and EB suggested decreased activity. In C57BL/6 mice, treatment with GLY and ciprofloxacin versus ciprofloxacin, significantly reduced clinical scores, plate count, and MPO. CONCLUSIONS: GLY decreases MDR by: altering bacterial parameters, including viability and efflux pump activity. In vivo, it increases the effectiveness of ciprofloxacin, reducing ocular disease, plate count, and MPO activity.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Hazlett LD, Ekanayaka SA, McClellan SA, et al. Glycyrrhizin Use for Multi-Drug Resistant Pseudomonas aeruginosa: In Vitro and In Vivo Studies. Invest Ophthalmol Vis Sci. 2019. PMID: 31311033. doi:10.1167/iovs.19-27200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。